SciELO - Scientific Electronic Library Online

vol.81 número6Estado Nutricional y Conductas Asociadas a la Nutrición en EscolaresMacrodistrofia Lipomatosa: Reporte de un Caso índice de autoresíndice de materiabúsqueda de artículos
Home Pagelista alfabética de revistas  

Servicios Personalizados



Links relacionados


Revista chilena de pediatría

versión impresa ISSN 0370-4106


KRAMER H, DANIELA et al. Propranolol in the Treatment of Infantile Hemangioma. Rev. chil. pediatr. [online]. 2010, vol.81, n.6, pp.523-530. ISSN 0370-4106.

Infantile Hemangiomas (IH) are common vascular tumors in children. Only 10-15%) should be treated by any vital, functional or aesthetic complications. Oral corticosteroids are the treatment of choice. However, in the last two years an excellent response to treatment of hemangiomas with oral Propranolol has been reported. Objective: evaluate this new therapy in a limited number of chilean patients with IH with an indication of systemic treatment and present this experience. Patients and Methods: We present 30 cases of IH treated at our institution with oral Propranolol, using a dose of 2 mg/kg/day divided in 2 daily doses. Results: 11% of patients were female, 40%o hemangiomas had segmental distribution, 90% were solitary, 61% were located in the head and neck and 23% were ulcerated. The treatment started at an average of 119 days of life and lasted for an average of 7 months. In all our patients the use of Propranolol accelerated the onset of involution of the hemangiomas and decreased color, brightness and growth too. 43% of the patients had irritability and sleep disorders. No significant adverse effects were reported in any of our patients. Conclusión: Propranolol treatment was highly effective and safe in our series of patients and we propose, taking into account published reports based on this data, it should become the treatment of choice for IH.

Palabras clave : Propranolol; Treatment; Infantile Hemangiomas.

        · resumen en Español     · texto en Español     · Español ( pdf )


Creative Commons License Todo el contenido de esta revista, excepto dónde está identificado, está bajo una Licencia Creative Commons